share_log

BTIG Assumes Akebia Therapeutics at Buy, Announces Price Target of $4

Benzinga ·  Nov 29, 2023 20:31

BTIG analyst Julian Harrison assumes Akebia Therapeutics (NASDAQ:AKBA) with a Buy rating and announces Price Target of $4.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment